A VHH single-domain platform enabling discovery and development of monospecific antibodies and modular neutralizing bispecifics against SARS-CoV-2 variants

Author:

Yang Marisa L1ORCID,Yuan Tom Z1ORCID,Chan Kara Y1,Ding Lin1,Han Zhen1,Franco Hector1,Holliday Carson1,Kannan Shruthi2,Davidson Edgar2,Doranz Benjamin J2,Chandran Kartik3,Miller Emily Happy4,Plante Jessica A56,Weaver Scott C56,Cho Eunice7,Kailasan Shweta7,Marsalek Lukas8,Giang Hoa1,Abdiche Yasmina9,Sato Aaron K1

Affiliation:

1. Biopharma Department, Twist Bioscience , South San Francisco, CA 94080 , United States

2. Integral Molecular , Philadelphia, PA 19104 , United States

3. Department of Microbiology and Immunology, Albert Einstein College of Medicine , Bronx, NY 10461 , United States

4. Department of Medicine, Albert Einstein College of Medicine , Bronx, NY 10461 , United States

5. World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch , Galveston, TX 77555 , United States

6. Department of Microbiology and Immunology, University of Texas Medical Branch , Galveston, TX 77555 , United States

7. Integrated Biotherapeutics , Rockville, MD 20850 , United States

8. Eyen SE , Prague , Czech Republic

9. Revelar Biotherapeutics, Inc. , Bethesda, MD 20817 , United States

Abstract

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, escape coronavirus disease 2019 therapeutics and vaccines, and jeopardize public health. To combat SARS-CoV-2 antigenic escape, we developed a rapid, high-throughput pipeline to discover monospecific VHH antibodies and iteratively develop VHH-Fc-VHH bispecifics capable of neutralizing emerging SARS-CoV-2 variants. By panning VHH single-domain phage libraries against ancestral or beta spike proteins, we discovered high-affinity VHH antibodies with unique target epitopes. Combining two VHHs into a tetravalent bispecific construct conferred broad neutralization activity against multiple variants and was more resistant to antigenic escape than the monospecific antibody alone. Following the rise of the Omicron variant, a VHH in the original bispecific construct was replaced with another VHH discovered against the Omicron BA.1 receptor binding domain; the resulting bispecific exhibited neutralization against both BA.1 and BA.5 sublineage variants. A heavy chain-only tetravalent VHH-Fc-VHH bispecific platform derived from humanized synthetic libraries held a myriad of unique advantages: (i) synthetic preconstructed libraries minimized risk of liabilities and maximized discovery speed, (ii) VHH scaffolds allowed for a modular “plug-and-play” format that could be rapidly iterated upon as variants of concern arose, (iii) natural dimerization of single VHH-Fc-VHH polypeptides allowed for straightforward bispecific production and purification methods, and (iv) multivalent approaches enhanced avidity boosting effects and neutralization potency, and conferred more robust resistance to antigenic escape than monovalent approaches against specific variants. This iterative platform of rapid VHH discovery combined with modular bispecific design holds promise for long-term viral control efforts.

Funder

Twist Bioscience Corporation

NIH

Publisher

Oxford University Press (OUP)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3